BCDA earnings analysis
What we found in BCDA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment data, or quantitative operating outlook, so quarter-over-quarter and year-over-year financial trends cannot be assessed. Market-risk exposure appears limited, with a 100-basis-point rate shock described as immaterial and cash equivalents maturing in less than three months. The principal disclosed incremental risk is potential Nasdaq delisting if continued-listing compliance is not maintained.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Limited Market-Risk Exposure
- Management reported no material changes in market risk during the three months ended June 30, 2026. A hypothetical 100-basis-point interest-rate change would have an immaterial pre-tax impact on results.
- Short-Dated Cash Portfolio
- Cash equivalents have maturities of less than three months, supporting the company’s stated objectives of capital preservation and liquidity maintenance.
- Controls Assessed Effective
- The CEO and CFO concluded that disclosure controls were effective at a reasonable assurance level as of June 30, 2026, with no material changes to internal control during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq Delisting Risk
- The company states that it was previously not in compliance with Nasdaq continued-listing requirements and could face delisting if it fails to maintain compliance as of June 30, 2026. Delisting could reduce trading volume and security price and make capital raising more difficult.
- Unhedged Interest-Rate Exposure
- The company does not hedge interest-rate exposure. Although management considers the impact of a 100-basis-point rate change immaterial, future changes in rates could affect cash investment income and borrowing costs.
- Foreign-Currency Exposure
- The company has foreign-currency transactions and does not currently use hedging strategies. Management said exposure was not significant at June 30, 2026, but it continues to evaluate potential hedging.
What they said about what is next.
No quantitative revenue or EPS outlook is included in the provided 10-Q excerpt; outlook appears deferred to other company communications.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- BioCardia reported net losses narrowing from $2.712 million in Q1 2025 to $2.259 million in Q1 2026, with no revenue noted again for this quarter. Operating expenses declined to $2.266 million from $2.726 million…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCDA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever